Inhibition of melanoma tumor growth in vivo by survivin targeting.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 11149963.
- Also identified by PMC identifier 14640.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A role of apoptosis (programmed cell death) in tumor formation and growth was investigated by targeting the apoptosis inhibitor survivin in vivo. Expression of a phosphorylation-defective survivin mutant (Thr(34)-->Ala) triggered apoptosis in several human melanoma cell lines and enhanced cell death induced by the chemotherapeutic drug cisplatin in vitro. Conditional expression of survivin Thr(34)-->Ala in YUSAC2 melanoma cells prevented tumor formation upon s.c. injection into CB.17 severe combined immunodeficient-beige mice. When induced in established melanoma tumors, survivin Thr(34)-->Ala inhibited tumor growth by 60-70% and caused increased apoptosis and reduced proliferation of melanoma cells in vivo. Manipulation of the antiapoptotic pathway maintained by survivin may be beneficial for cancer therapy.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Apoptosis
- Cisplatin
- Gene Targeting
- Melanoma
- Melanoma, Experimental
- Microtubule-Associated Proteins
- Neoplasm Proteins
- Proteins